Oxidative modification of lipoproteins is believed to be important in the genesis of atherosclerosis. We established cultures of smooth muscle cells (SMC) and exposed them to native LDL or oxidized LDL. Oxidized LDL, but not native LDL, was mitogenic as measured by incorporation of [3HI -thymidine into DNA. This effect was concentration dependent, averaged 288% of control, and was blocked by a platelet-activating factor (PAF) receptor antagonist. We hypothesized that phospholipids with PAF-like activity were generated during the oxidation of LDL. To test this hypothesis we extracted phospholipids from copper-oxidized LDL and assayed for PAF-like activity. Phospholipids extracted from oxidized LDL and purified by HPLC induced neutrophil adhesion equivalent to PAF (10 nM) and were mitogenic for smooth muscle cells. These effects were not seen with phospholipids extracted from native LDL and were blocked by two structurally different, competitive antagonists of the PAF receptor. The effects of these lipids were also abolished by pretreating them with PAF acetylhydrolase. Finally, we used Chinese hamster ovary cells that had seen stably transfected with a cDNA for the PAF receptor to confirm that phospholipids from oxidized LDL act via this receptor. We found that PAF (control) and the oxidized phospholipids each induced release of arachidonic acid from the transfected cells, but had no effect on wildtype Chinese hamster ovary cells, which lack the PAF receptor. This effect was also blocked by a PAF receptor antagonist. Thus, phospholipids generated during oxidative modification of LDL may participate in atherosclerosis by stimulating SMC proliferation and leukocyte activation. (J. Clin. Invest. 1995.96:2322-2330
Introduction
Increased levels of LDL are strongly associated with an increased risk of atherosclerosis (1) (2) (3) . The mechanisms by which elevated levels of LDL lead to atherosclerosis are not fully elucidated. However, there is evidence that LDL must be modified to become pathogenic (4) (5) (6) . Modification of LDL may be accomplished in vitro by a variety of chemical methods, including oxidation, or by incubation with one of the cell types found in the vascular wall (endothelial cells, macrophages, or smooth muscle cells) (7, 8) . Several experimental findings indicate that the cell-mediated modification of LDL is due to the generation of oxidants by the cells (8, 9) . This is an attractive hypothesis as it could explain how LDL modification occurs in vivo and is supported by studies in animals that have shown a protective effect of antioxidants against atherosclerosis (10) (11) (12) (13) . Regardless of the mechanisms of LDL modification, once it has occurred the LDL particle (specifically the apolipoprotein B-100) is no longer recognized by the LDL receptor (14). Instead, the modified LDL is recognized by a scavenger receptor which is abundant on endothelial cells (ECs) and macrophages ( 15, 16) . This change is significant in that the LDL receptor is downregulated in response to LDL uptake by a negative feedback mechanism, whereas the scavenger receptor is not under negative feedback control. This allows large amounts of cholesterol from modified LDL to accumulate in cells via this receptor. Unregulated uptake of modified LDL by macrophages leads to their transformation into foam cells, which are components of the first histologically visible lesion of atherosclerosis-the fatty streak.
In addition to the deposition of cholesterol, atherosclerotic lesions are characterized by the proliferation of smooth muscle cells (SMC)' and by the infiltration of monocytes and macrophages. Modified LDL may affect these cellular processes as well. It is known that modified LDL is toxic to endothelial cells, attracts monocytes, and inhibits the mobility of macrophages (6) . The recruitment of monocytes to the vascular wall may also involve indirect mechanisms. For example, LDL that has been minimally modified induces transcription and translation of the gene for monocyte chemotactic protein-I in smooth muscle cells (17) and induces endothelial cells to produce Gm-CSF (18) . Modified LDL also inhibits endothelium-dependent vasorelaxation and potentiates vasoconstriction (19) (20) (21) . Several investigators have studied the effects of LDL and modified LDL on smooth muscle cell proliferation. Fless et al. found that human LDL particles were mitogenic for smooth muscle cells cultured from monkey aorta (22) . Koschinsky noted a small mitogenic effect of LDL from hypercholesterolemic, but not from normocholesterolemic, human blood donors (23) . Others have found that LDL increased the turnover of phosphatidylinositol in rat and human arterial smooth muscle cells implying a 1 . Abbreviations used in this paper: BHT, butylated hydroxytoluene; DFP, diisopropylfluorophosphate; PAF, platelet-activating factor; SMC, smooth muscle cell. stimulatory effect on cellular proliferation (24, 25) . The latter group also noted an increase in intracellular pH, translocation of protein kinase C to the cell membrane, and protooncogene expression. Surprisingly, they did not find an increase in incorporation of [3H]thymidine. Sachinidis et al. (26, 27) found that LDL from normocholesterolemic donors increased intracellular pH and calcium concentrations in smooth muscle cells from rat aorta. In these experiments [3H]thymidine incorporation was increased indicating that cellular proliferation was stimulated. The same group later reported that oxidized LDL caused a greater increase in intracellular calcium that native LDL (28) . Finally, Resink et al. found that oxidized LDL increased phosphatidylinositol turnover by a larger amount than did native LDL in smooth muscle cells from human arterioles (29) . They concluded that the process was mediated by a receptor that recognized a modified protein, as lipid extracts from native LDL had no effect.
LDL is 75% lipid by weight, and the polyunsaturated fatty acids in phospholipids and cholesterol esters may be the initial sites of oxidative attack during modification of the particle. There is evidence that the products of these reactions modify the apolipoprotein (14, 30) Further, lyso-phosphatidylcholine (lyso-PC) is produced during LDL oxidation; and monocyte recruitment (31) the inhibition of endothelium-dependent relaxation (19, 20) and smooth muscle cell growth (32, 33) have been attributed to this compound.
We and others have shown that phospholipid autacoids are important intercellular messengers in both physiologic and pathologic situations (reviewed in reference 34). Platelet-activating factor (PAF) activates platelets and leukocytes, and increases vascular permeability among other actions. Initially identified as a mediator of anaphylaxis in rabbits, PAF is now recognized to be synthesized by, and to act upon, many types of cells. For example, Stoll and Spector (35) reported that PAF is a mitogen for vascular SMC and that it is synergistic with PDGF in this effect. PAF was the first phospholipid for which a receptor was identified, and the cDNA for this receptor has now been cloned and expressed in cell lines (36, 37) . The PAF receptor is specific for choline phosphoglycerides with a short chain fatty acyl residue at the sn-2 position. Work in our laboratory has focused on the role of PAF in recruiting neutrophils through its expression on the surface of activated endothelial cells. We have also shown that oxidatively fragmented phospholipids (PAF-like lipids) are recognized by the PAF receptor and have similar bioactivity (38, 39 ) . These PAF-like lipids have been produced by exposure of synthetic phosphatidylcholine (PC) to ozonolysis or to lipoxygenase (38) , and by exposing cultured cells to oxidants (39) . These compounds are inactivated by PAF acetylhydrolases (40, 41) , a family of enzymes that specifically degrade PAF and related compounds by cleaving the ester bond at the sn-2 position. Like the receptor, this enzyme is specific for choline phosphoglycerides that have a short chain fatty acid at the sn-2 position (42) . Interestingly, the plasma form of PAF acetylhydrolase is associated with lipoproteins, primarily LDL, but also HDL (42, 43) . Klimov et al. (44) showed that a coincubation of HDL with LDL inhibited iron-induced oxidation of LDL, and Parthasarathy et al. (45) demonstrated a protective effect of HDL on cell-induced oxidation of LDL. We showed that HDL slows the oxidation of LDL, and that much of the protection depends on the presence of PAF acetylhydrolase (46) . Watson and colleagues also found that PAF acetylhydrolase prevented the development of minimally modified LDL, implicating a PAF-like lipid in the process (47) .
In the studies reported here we tested the hypotheses that oxidatively modified LDL BSA-containing medium without additions was used as the control. PDGF at different concentrations, but usually at 1 ng/ml, was used as a positive control. The assays were carried out in triplicate for each condition in each experiment. For lipoprotein-containing solutions, the concentration of BSA was adjusted to keep the total protein concentration constant.
The cells were always examined by inverted phase-contrast microscopy at the initiation and conclusion of each incubation, and we found a qualitatively concordant result with the thymidine incorporation. Additionally, in several control experiments we determined the number of cells before and after stimulation and found an excellent correlation with thymidine incorporation.
Assay of rat AJO cell growth. 18 h before the cells were to be used the medium was removed and replaced with DME containing 1% FCS. The test compound was dissolved in PBS containing 0.1% BSA, warmed to 370C, and added to the cells. PDGF at 30 ng/ml was used as a positive control. The cells were incubated at 370C for 18 h. The medium was then supplemented with 1 1iCi of [3H]thymidine for 1 h. The medium was removed and ice-cold 25% trichloroacetic acid was added. Precipitated material was washed three times with 25% trichloroacetic acid then solubilized in 0.25 N NaOH. (50) . Separation of total lipids into neutral lipids, fatty acids, and phospholipids was done on aminopropyl columns using sequential elution with 67% chloroform/ 33% isopropanol, then 1% acetic acid in diethyl ether, and finally methanol (51) . Further purification of the phospholipid fraction was accomplished by reversed-phase HPLC using a 250 x 4.6 mm ODS column (5 y Microsorb MV; Rainen Instrument Co., Woford, MA.) and a mobile phase of 84% methanol/ 15% acetonitrile/ 1% deionized water containing 1 MM ammonium acetate at a flow rate of 1 ml/min. The effluent was collected in I-,1 fractions. In additional experiments we used another HPLC system with the same column but a gradient mobile phase (system 2) to achieve better separation of the active material. In this procedure we used the same solvent as above as solvent B, while solvent A was the same composition but with 10% water. The gradient protocol was a continuous flow rate of 1 ml/min beginning with 100% solvent A until 5 min after injection. At that time we began a linear gradient to 100% solvent B at 55 min. In this system, PAF elutes at 13 min, lysophosphatidylcholine at 8-9 min, and phosphatidylcholine at 25-26 min.
Assays for PAF-like bioactivity. We used two assays for quantifying PAF-like bioactivity. In the first, neutrophils were isolated from human blood (52), placed in gelatin-coated wells and then the test compounds were added for a 10-min incubation (53) . The nonadherent cells were removed by washing and the number of adherent cells was counted with a video microscopy system that images 20% of the well. Authentic PAF and FMLP were used as positive controls and buffer alone was the negative control. Adhesion in this assay is dependent on activation of neutrophils with functional upregulation of the /2-integrin CDllb/ CD18 (38) .
In the second assay we used Chinese hamster ovary (CHO) cells that had been stably transfected with the human PAF receptor as a target for PAF-like actions. These cells were a gift from Dr. Patrick Gray (ICOS Corp., Bothell, WA). The cDNA encoding the PAF receptor (in pcDNA/Neo) was transfected into CHO cells with Lipofectin. Stable transfectants were selected by growth in medium that contained 600 MM G418. To assay responses to PAF and oxidized phospholipids the transfected cells and wild-type CHO cells (which lack the PAF receptor and do not respond to PAF) were incubated with [3H] arachidonic acid (0.5 /Ci/ml) in fatty acid-free BSA for 3 h. The principle of the assay is that the PAF receptor is functionally coupled to phospholipase A2 and causes release of arachidonate in many cell types (34) . After labeling, the cells were washed with buffer that contains fatty acid-free bovine serum albumin to remove arachidonic acid that had not been incorporated into cellular lipids. The cells were then stimulated with PAF, test compounds such as oxidized phospholipids, or control medium containing calcium ionophore A23187 (positive) or buffer alone (negative). The supernatant was removed and the amount of [3H] arachidonic acid released was determined by scintillation spectrometry. When incubated with PAF the CHO transfectants released radiolabeled arachidonic acid. This response was dependent on the concentration of PAF, and was blocked by antagonists of the PAF receptor. Wild-type CHO cells did not respond to PAF, nor did CHO cells transfected with vector alone.
Results
Some groups have shown that LDL stimulates the growth (or related responses) of smooth muscle cells while others have found no effect (22, (24) (25) (26) (27) . We reexamined the hypothesis that oxidized LDL accounted for the growth-stimulatory actions. In initial studies we found that LDL, which we assumed was in its native state, and LDL that we had purposefully oxidized both stimulated the incorporation of [3H]thymidine into smooth muscle cells (not shown). However, when blood was drawn directly into tubes containing an antioxidant (BHT) and a chelator of transition metals (EDTA), and these compounds were kept present during the entire isolation and preparation of LDL, we found that the LDL that had been protected from oxidation did not stimulate smooth muscle cells to incorporate thymidine into DNA (n = 3). In these same experiments, we tested the effect of LDL that was prepared from blood that had not had the antioxidant added at the time of collection, and then had been oxidized by exposure to copper sulfate. This oxidized LDL consistently stimulated the growth of smooth muscle cells (Fig. 1) . We excluded the possibility that the differences observed in the two forms of LDL was the result of a direct inhibitory effect of BHT on the cells by adding it to the same final concentration in the oxidized LDL preparation after the Fig. 2 . However, we did not consistently find synergism with PDGF, which was a strong growth stimulus alone. This discrepancy with the results of Stoll and Spector (35) may reflect the differences in tissues and species used.
We next tested whether a synthetic, oxidized phospholipid, 1-palmitoyl-2-[5-oxovaleroyl]-sn-glycero-3-phosphocholine (5-AL-PC), could also stimulate smooth muscle cell growth.
This compound, which is derived from oxidation of arachidonate in the precursor phospholipid, stimulates neutrophils 250- through the PAF receptor (38, 40) . We found that 5-AL-PC stimulated the incorporation of [3H] thymidine in seven of eight experiments and that the maximal effect averaged 133±8% of control. The peak response occurred at concentrations between 1 and 10 nM. This stimulatory effect was abolished in experiments in which we blocked the receptor for PAF on the smooth muscle cells with WEB 2086 (10 uMM), a competitive antagonist (38) of the receptor (n = 2). As expected, this antagonist also blocked the response to PAF, but had no effect on the response to PDGF (positive control) or medium alone (negative control).
These results were consistent with the hypothesis that oxidized phospholipids structurally related to PAF could account for the growth-promoting action of oxidized LDL on smooth muscle cells. We examined this further by testing whether blockade of the PAF receptor would alter the proliferative response to oxidized LDL. We pretreated the cells with WEB 2086 (10 MM) before exposing them to oxidized LDL, and included it during the coincubation. This completely blocked the growth-stimulating effect of oxidized LDL (Fig. 3) . This suggested that oxidatively fragmented phospholipids in oxidized LDL are agonists for the growth of smooth muscle cells, and that they are generated during the oxidation process. Moreover, it indicated that all of the mitogenic activity was mediated through the PAF receptor on smooth muscle cells.
We next addressed the latter issue directly: were there PAFlike bioactive phospholipids in oxidized LDL? In our initial experiments, the effects of an unfractionated extract from oxidized LDL on PMN adhesion were not reproducible, activity was observed in some experiments but not all, and high concentrations of lipid were required. One possibility was that active phospholipids were present but not in solution or otherwise lacked access to the PAF receptor (e.g., they were sequestered in a micelle) due to the large amounts of cholesterol esters and triglycerides. Another possibility was that PAF-like oxidized phospholipids were generated, but had been hydrolyzed by the action of PAF acetylhydrolase. We addressed the first problem by isolating the phospholipids via aminopropyl column chromatography. The second problem was addressed by chemically inactivating the PAF acetylhydrolase in some of the LDL samples and then carrying out an oxidation reaction. We found (Fig. 4) We next turned to isolation and characterization of the bioactive lipid(s). We extracted the lipids from oxidized LDL, and separated the neutral lipids, fatty acids, and phospholipids. Bioactivity, measured as the ability to induce PMN adhesion, was entirely in the phospholipid fraction and was blocked by a PAF receptor antagonist (Fig. 5) . This preparation of phospholipid was used for additional separation by reversed-phase HPLC. Fractions eluted from the HPLC column were dried, resuspended, and tested for bioactivity (Fig. 6) . We found that the fractions that eluted at 6, 7 (peak), and 8 min contained activity that induced PMN adhesion. Activation of PMNs by these HPLC fractions was again blocked with PAF receptor antagonists (data not shown). We also used this purification scheme to test for bioactivity in extracts of control LDL that had not been DFP-treated or oxidized, but found none (Fig. 6) . In this HPLC system, lyso-phosphatidylcholine was eluted at 5 min, authentic PAF at 6 min, and phosphatidylcholine at 21 min. Thus, the active compounds were significantly more polar than phosphatidylcholine, but less polar than lyso-phosphatidylcholine,which is an identical profile to what we and others have reported for oxidized phospholipids (39) . The fact that PAF elutes at 6 min in this system indicates that the active compound is structurally similar to PAF. But there are compelling arguments, in addition to this physical separation, that it is not PAF. First, we assayed our LDL samples for PAF acetyltransferase, which is required for PAF synthesis, and found no activity. Second, we analyzed the fractions with bioactivity for PAF by mass spectrophotometry and found none (54 tions were collected every minute for 30 min. The samples were dried (N2) and then resuspended in HBSS with albumin for inclusion in the neutrophil adhesion assay as previously described. The results are expressed as number of neutrophils adherent to gelatin-coated plates from a single experiment that is representative of five. Neutrophil adhesion stimulated by the oxidized LDL lipids was blocked by incubation with a PAF receptor antagonist (data not shown).
LDL contains phospholipids that have undergone fragmentation of unsaturated fatty acids to yield compounds with pronounced autacoid activity.
The evidence at this point strongly supported the conclusion that the lipids extracted from oxidized LDL acted via the PAF receptor on target cells, but it was possible that other receptors were mediating the actions and that the inhibition by PAF receptor antagonists was nonspecific. To exclude this possibility, we assayed the effects of the fractions from the HPLC purification on CHO cells stably expressing the cloned human PAF receptor. The fractions (6-8) that had effects on PMNs also stimulated the release of arachidonate from the transfected cells, but not from the wild-type cells (Fig. 7) . This effect was similar in magnitude to authentic PAF, and was blocked by the receptor antagonist. This result unequivocally demonstrated that the effect of these lipids was mediated via the receptor for PAF.
We then returned to the smooth muscle cell assay, this time using cells cultured from rat aorta, to determine if the HPLC fractions that had been active in the neutrophil and CHO cell assays would stimulate smooth muscle cell proliferation. HPLC fractions with PAF-like activity in the other assays also stimulated smooth muscle cell growth to 218±10% of control (four experiments with each conducted in triplicate). The same HPLC fractions from extracts of native LDL had no effect (Fig. 8) . The mitogenic effect of the active fractions from oxidized LDL was blocked completely by the addition of a PAF receptor antagonist (two experiments using WEB 2086 at lOM). In an additional set of experiments we collected the active fractions from the first HPLC separation and further fractionated them on the same column but with a different mobile phase (system 2 in Methods). In two experiments we found that compound(s) that eluted at 19 min stimulated the growth of smooth muscle cells and activated PMNs, and that both actions were via the PAF receptor.
To further characterize the bioactive phospholipid, we treated the positive HPLC fractions with PAF acetylhydrolase, which is specific for short-chain residues at the sn-2 position of phosphoglycerides (55, 56) . As shown in Fig. 9 , this treatment abolished the activity in HPLC fractions 6-8, while a shamincubation had no effect. Thus, the active oxidized phospholipids must have a short (or oxidized) acyl chain at the sn-2 position.
Discussion
Previous studies of the effects of LDL on vascular smooth muscle cell proliferation have reported variable results, although most workers have found stimulatory effects. Our experiments show that LDL protected with an antioxidant does not stimulate SMC proliferation, while oxidized LDL does. This suggests that some modification begins during the isolation procedure or perhaps is induced by the SMC themselves. The changes must be subtle as no differences were detected by changes in agarose mobility. As a technical point, this may explain the discrepancies in the previous studies. From a biological perspective, it indicates that the oxidation of LDL in vivo may generate compounds that stimulate the growth of smooth muscle cells. This could have important consequences in the pathogenesis of atherosclerosis since proliferation of these cells is a central feature of the disease, and because LDL is thought to be oxidatively modified at the site of atherosclerosis. The stimulatory effects of oxidized LDL, PAF, and 5-AL-PC were all blocked by an antagonist to the PAF receptor. Moreover, we directly demonstrated that a phospholipid(s) with physicochemical properties similar to PAF is generated by the oxidation of phospholipids in LDL and acts via the PAF receptor.
We identified a PAF-like compound in lipid-extracts of oxidized LDL by demonstrating that it stimulates neutrophil adhesion, activates CHO cells transfected with the PAF receptor, and stimulates SMC growth. Lysophosphatidylcholine has a variety of effects on smooth muscle cells (31-33) so it was a candidate to explain our observations. However, in our experiments lysophosphatidylcholine was not active in the neutrophil and CHO cell assays. Also, the bioactive compound was inactivated by PAF acetylhydrolase, which hydrolyzes short acyl chains at the sn-2 position of phospholipids (55, 56) but has no effect on lysophosphatidylcholine. The be an oxygen-containing substituent on this short chain. Benveniste and coworkers described the appearance of phospholipids with PAF-like activity when LDL was left exposed to air for long periods (57) . They interpreted this as the release of "preformed" PAF from a cryptic site in the LDL particle. However, the active compound(s) had a retention time on HPLC that was clearly different from PAF and very similar to what we and others have shown for oxidized phospholipids. Thus, we suspect that the activity they described resulted from oxidative fragmentation of phospholipids in the LDL particles.
Although we were able to purify the active fractions extensively and show that they were phospholipids that had been oxidatively fragmented, we do not yet know their precise structure. Studies are in progress to determine the molecular structure of the active compounds from LDL. However, the chemistry of oxidized lipids is complicated and it is likely that there will be several compounds, as we observed even when a single synthetic phospholipid was used as the substrate (40) . Further, it is likely that ratios of the oxidized products will change under different conditions. Tokomura et al. defined several oxidatively fragmented phospholipids isolated from a bovine brain lipid extract (58) and many of these were compounds that we described following the oxidation of l-O-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (40) .
The inhibition of the PAF acetylhydrolase in LDL with DFP was an important technical point since it allowed the oxidized phospholipid to accumulate, which was essential for us to identify the biological activity. More importantly, this observation suggests that the PAF acetyihydrolase plays an important role in vivo, since removal of these compounds should mitigate the atherosclerotic process or other forms of vascular injury. Indeed, others have shown that HDL protects LDL from oxidation in vitro, a process which might explain some of its ability to lower the risk of vascular disease (44, 45) . The recent findings that the slowing of LDL modification in vitro by HDL depends on active PAF acetylhydrolase (46, 47) are complementary to the results reported here. Aldehydes and other reactive compounds are formed from the polyunsaturated fatty acids at the sn-2 position of phospholipids during the oxidation of LDL, and these compounds can derivatize the apoprotein (14, 30). We conclude that the PAF acetylhydrolase protects by catalyzing the hydrolysis of such reactive groups, permitting them to diffuse away from the LDL particle or to be inactivated by some physiologic mechanism (i.e., reacting with albumin). This may be a key advantage resulting from the association of this enzyme with lipoproteins. However, this protective mechanism may be lost in strongly oxidizing environments since PAF acetylhydrolase is inactivated by oxidants (46, 59, 60) . Prevention of this inactivation may be an important effect of antioxidant therapy since it would preserve an enzymatic activity with antiinflammatory and antiatherogenic properties.
The present work also suggests a more direct role for oxidized phospholipids in vascular pathology. We 
